Linden Capital Partners (“Linden”), a Chicago-based healthcare private equity firm, announced a majority investment in Vital Care, Inc. (“Vital Care” or the “Company”) alongside current shareholders (the Bell family) and management. Founded in 1986 and headquartered in Meridian, Mississippi, Vital Care is the premier franchisor of home infusion services, with franchises serving a wide range of patients including those with chronic conditions as well as acute conditions. The Company supports over 50 franchises across 20 states with a focus on the underserved secondary markets.
IVX Health, a national provider of infusion and injection therapy for patients with complex chronic conditions such as multiple sclerosis, Crohn’s disease, and rheumatoid arthritis, announced Wednesday its acquisition of Precision Healthcare, formerly a subsidiary of BAI Healthcare Services, Inc. Based in Nashville, Tenn., Precision operates 12 infusion centers across Tennessee and northern Arkansas. The acquisition financing was led by a preferred equity investment from Linden Capital Partners – a Chicago-based private equity firm focused exclusively on the healthcare sector – and joined by existing institutional investors McKesson Ventures, Health Velocity Capital, and Nueterra Capital.
An affiliate of Peak Rock Capital (“Peak Rock”), a leading middle-market private equity firm, announced today that it has completed its acquisition of Paragon Healthcare, Inc. (“Paragon” or the “Company”) in partnership with the management team of the Company. Paragon is a leading provider of ambulatory and home infusion services and specialty pharmacy services. The Company provides comprehensive, high quality infusion services to patients with chronic health conditions and those in need of post-acute care. Headquartered in Dallas, Texas, with pharmacy and infusion operations in Alabama, Georgia, Tennessee, Louisiana, Texas, Oklahoma, Colorado, Oregon, and Washington, the Company has built an excellent reputation in the industry for its service to patients across lower-cost settings of care, including infusion centers, patient homes, and physician’s offices.
KabaFusion, a leading provider of specialty acute and chronic home infusion therapies, today announced it has acquired the home infusion assets of Lincare, a subsidiary of Linde plc. The strategic combination strengthens KabaFusion’s position as the premier clinician-led home infusion company in the United States, significantly enhancing the company’s ability to deliver superior patient care across a broad range of home infusion therapies nationwide. KabaFusion, led by founder Dr. Sohail Masood, has been a pioneering leader in patient-focused home infusion services with deep clinical expertise in intravenous immunoglobulin (IVIG) therapies. The addition of Lincare’s infusion operations expands KabaFusion’s footprint to 28 home infusion specialty pharmacies, adding key strategic markets in Alabama, Arkansas, Florida, Indiana, Kentucky, Michigan, New Jersey, New York, North Carolina, Virginia and Wyoming.
The PromptCare Companies (“PromptCare” or the “Company”), a leading regional provider of complex respiratory and specialty home infusion services, announced it has acquired Premier Specialty Infusion (“Premier”) from the family of the CEO, Mr. Ashar Hasan. The acquisition will further expand PromptCare’s footprint in the Midwestern United States. Terms of the transaction were not disclosed. Founded in 2017, Premier is a Hoffman Estates, IL-based provider of specialty home infusion services with a primary focus on managing immunoglobulin therapy (IVIG) for patients with neuroimmunology conditions in select markets within the United States. PromptCare is a portfolio company of The Halifax Group.
Infusion Management announced the completion of a majority recapitalization and growth equity capital raise with Cimarron Healthcare Capital (CHC). Infusion Management is the exclusive management services organization (“MSO”) affiliated with Infusion for Health, the premier clinical provider of infusion therapy treatment for patients with multiple sclerosis, rheumatoid arthritis, and other autoimmune and immunodeficiency disorders in the greater Los Angeles area. CHC is a Salt Lake City-based private equity firm focused on healthcare investments in the lower middle market. Financial terms of the transaction were not disclosed.
Option Care Enterprises, Inc. (“Option Care”) and BioScrip, Inc. (“BioScrip”) today announced the successful completion of their merger, which follows the satisfaction of the transaction’s closing conditions, including approval by BioScrip shareholders and the receipt of all necessary regulatory approvals. The newly combined company, Option Care Health, Inc. (“Option Care Health” or the “Company”), emerges as the largest independent home and alternate site infusion services provider in the United States. Option Care Health’s common stock will be listed on the Nasdaq Global Select Market under the ticker symbol BIOS.
BioScrip, Inc. (NASDAQ: BIOS) (“BioScrip” or the “Company”), the largest independent national provider of infusion and home care management solutions, announced Friday that its stockholders approved the proposals that are conditions to the proposed merger with Option Care at the Company’s special meeting of stockholders held earlier today. BioScrip’s merger with Option Care is expected to close on or about August 6, 2019.
BioScrip, Inc. (NASDAQ: BIOS) (“BioScrip” or the “Company”), the largest independent national provider of infusion and home care management solutions, today provided an update on its proposed merger with Option Care Enterprises, Inc. (“Option Care”). The Company received notification on April 8, 2019, that early termination of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”) waiting period has been granted for the Company’s proposed merger with Option Care. The Company continues to anticipate that its merger with Option Care will close in the second half of 2019.
BioScrip, Inc. (NASDAQ: BIOS) (‘BioScrip’) and Option Care Enterprises, Inc. (‘Option Care’), the nation’s largest independent providers of home and alternate treatment site infusion therapy services, today announced that they have entered into a definitive merger agreement. The combination is expected to create a leading independent provider with the national reach, comprehensive therapy offering and financial capacity to succeed in the attractive and growing home and alternate site infusion services segment of the $100 billion U.S. infusion market. Under the terms of the merger agreement, BioScrip will issue new shares to Option Care’s shareholder, which is owned by investment funds affiliated with Madison Dearborn Partners, LLC (‘MDP’) and Walgreens Boots Alliance, Inc. (NASDAQ: WBA) (‘WBA’), in an all-stock transaction. Upon completion of the transaction, MDP funds and WBA will beneficially own approximately 80% of the combined publicly traded company on a fully diluted basis, with current BioScrip shareholders holding the remainder.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.